Tango Therapeutics Files DEFA14A Proxy Materials
Ticker: TNGX · Form: DEFA14A · Filed: Apr 17, 2026
Sentiment: neutral
Topics: proxy-filing, shareholder-materials, sec-filing
TL;DR
TANGO filed more proxy docs 4/17/26 - check for shareholder votes.
AI Summary
Tango Therapeutics, Inc. filed a DEFA14A on April 17, 2026, related to additional definitive proxy soliciting materials. The filing includes several graphic documents and a complete submission text file, with the company's mailing and business address listed as 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215.
Why It Matters
This filing indicates Tango Therapeutics is providing additional information to shareholders, likely related to upcoming corporate actions or proposals requiring shareholder vote.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not inherently indicate significant new risks for the company.
Key Players & Entities
- Tango Therapeutics, Inc. (company) — Filer
- 0001819133 (company) — CIK Number
- 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (company) — Mailing and Business Address
- 0001193125-26-160320 (dollar_amount) — SEC Accession Number
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing is used for additional definitive proxy soliciting materials and Rule 14(a)(12) material, meaning the company is providing further information to shareholders, often in advance of a shareholder meeting or vote.
When was this DEFA14A filing accepted by the SEC?
This DEFA14A filing was accepted by the SEC on April 17, 2026, at 07:42:24.
What is Tango Therapeutics' business address?
Tango Therapeutics' business address is 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215.
What is the CIK number for Tango Therapeutics, Inc.?
The CIK number for Tango Therapeutics, Inc. is 0001819133.
What type of documents are included in this filing?
This filing includes a DEFA14A document, three graphic files (JPGs), and a complete submission text file (.txt).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 17, 2026 regarding Tango Therapeutics, Inc. (TNGX).